These findings suggest that GLP-1 receptor agonists may have kidney-protective effects in lupus nephritis, likely due to their anti-inflammatory properties
The Medicare GLP-1 Bridge will provide coverage of three GLP-1s (Wegovy, Zepbound, and Foundayo) that have been approved by the FDA for chronic weight management in adults with obesity (BMI of 30 or more) or adults with overweight (BMI of 27 or more) plus a weight-related comorbid condition
Like other GLP-1 receptor agonists, oral semaglutide also carries a black box warning for potential risk of thyroid C-cell tumors and a contraindication for use in patients with a personal or family history of medullary thyroid cancer or in patients with multiple endocrine neoplasia syndrome type 2
The exception is semaglutide which seems to have a better safety profile than the other GLP-1s available
It makes constipation harder to resolve, increases the concentration of bile acids that irritate the gut lining, reduces the volume of protective mucus, and impairs the motility that probiotics are trying to support
